Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves

This study sought to determine the anti-SARS-CoV-2 antibody status of 4111 Thai people from May 2020 to April 2021, a period which spanned the first two and part of the third epidemic wave of the COVID-19 in Thailand. Participants comprised 142 COVID-19 patients, 2113 individuals at risk due to their occupations [health personnel, airport officers, public transport drivers, and workers in entertainment venues (pubs, bars and massage parlors)], 1856 individuals at risk due to sharing workplaces or living communities with COVID-19 patients, and 553 Thai citizens returning after extended periods in countries with a high disease prevalence. All sera were tested in a microneutralization assay and a chemiluminescence immunoassay (CLIA) for IgG against the N protein. Furthermore, we performed an immunofluorescence assay to resolve discordant results between the two assays. Antibody responses developed in 88% (15 of 17) of COVID-19 patients at 8 days and in 94-100% between 15 and 60 days after disease onset. Neutralizing antibodies persisted for at least 8 months, longer than the IgG did, against the N protein. None of the health providers, airport officers, and public transport drivers were seropositive, while the antibodies were present in 0.44% of entertainment workers. This study showed the seropositivity of 1.9, 1.5, and 7.5% during the 3 epidemic waves, respectively, in Bangkok residents who were at risk due to sharing workplaces or communities with COVID-19 patients. Also, antibody prevalence was 1.3% in Chiang Mai people during the first epidemic wave, and varied between 6.5 and 47.0% in Thais returning from high-risk countries. This serosurveillance study found a low infection rate of SARS-CoV-2 in Thailand before the emergence of the Delta variant in late May 2021. The findings support the Ministry of Public Healths data, which are based on numbers of patients and contact tracing.


56
On 13 January 2020, Thailand was the first country to report a confirmed coronavirus 57 disease-19 (COVID-19) case outside of China. The first indigenous case in Thailand occurred on 58 30 January 2020 in a local taxi driver who had no history of traveling abroad; investigation 59 suggested that he was exposed to the severe acute respiratory syndrome coronavirus-2 (SARS-  People infected with SARS-CoV-2 may develop antibodies targeting multiple viral 86 proteins, regardless of whether they have symptoms or not. Therefore, serosurveillance was an 87 important tool for estimating the magnitude and monitoring the epidemic, especially since 88 asymptomatic cases were common. A meta-analysis showed that the as many as 35% of cases were shown that neutralizing antibodies persist in a majority of COVID-19 cases for up to 13 months . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269501 doi: medRxiv preprint entertainment venues (e.g., pubs, bars, and massage parlors). 3) People at risk due to sharing 115 workplaces or communities with COVID-19 patients. In the enrollment process for participants in 116 groups 2 and 3, epidemiologists explained the purpose of the study to obtain written consent for 117 interviewing about their demographics, occupation, workplace, residence, and general health 118 condition, including a donation of 5-8 ml of blood, with specimens labeled using ID codes. 4) Thai 119 citizens in state quarantines, when arrived Thailand after extended duties in countries with known   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

164
The assay required a minimal volume of 150 µl of test serum to fill the reaction cup. Acridinium-

Statistical analysis
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022.   (R 2 = 0.6042) (Fig 3). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022.    is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269501 doi: medRxiv preprint 219 We conducted serosurveillance in 1856 Thai people at risk by sharing the same workplaces 220 or living in the same community with COVID-19 cases. The investigation showed that 1.9% (11 221 of 574), 1.5% (6 of 388), and 7.5% (11 of 147) of people in Bangkok were seropositive for anti-222 SARS-CoV-2 antibody during the three epidemic waves, respectively. In Chiang Mai, 1.3% (10 223 of 747) of participants were seropositive during the first epidemic wave; 7 of them provided 224 histories of having COVID-19 during the prior 8 months ( is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Serological profiles of anti-SARS-CoV-2 antibodies in participants at
231 risk 232 We display in Tables 1 and 2 the serological profiles of anti-SARS-CoV-2 antibodies in 233 3969 participants, grouped as 2113 people at risk by occupation (Table 1)  Furthermore, the NT antibody titers were not well correlated with the IgG levels obtained by CLIA 239 (R 2 = 0.5908) (Fig 4).  (Table 3).

248
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022.   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269501 doi: medRxiv preprint microNT assay and Architect IgG were not significantly different. Nevertheless, NT antibody titers 264 were not well correlated with the IgG levels.

265
Our study in COVID-19 patients showed that 15 of 17 (88.2%) patients mounted a 266 detectable antibody response 8-14 days after onset of symptoms. However, the prevalence 267 increased to as high as 94-100% in the subsequent 45 days. In addition, we found that anti-SARS-

268
CoV-2 antibodies persisted for at least 8 months in all 7 individuals who had a history of COVID-269 19, while Architect IgG to N protein did not last that long. This is similar to the findings of others   Nevertheless, the occurrence of the second and third epidemic waves came very abruptly, from 303 introduction of the newer variants, the GH clade and the Alpha variant, respectively. We cannot 304 deny that these outbreaks due to illegal activities, including cross border movement of migrant 305 workers and gamblers.

306
Before the third epidemic wave trended down, the outbreak situation of SARS-CoV-2 307 became worse due to introduction of the Delta variant (that is more transmissible and virulent) to 308 seed a fourth epidemic wave. The infection rate peaked in August 2021, when more than 20000 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 21, 2022.    . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269501 doi: medRxiv preprint SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022. October 20]. Available from: https://ourworldindata.org/coronavirus/country/thailand. 379 380 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269501 doi: medRxiv preprint